Sympathomimetic alpha and beta-agonist
Dopaminergic agonist
CCP: Symptomatic hypotension in the absence of hypovolemia (e.g., cardiogenic shock, bradycardia, sepsis, renal failure)
CCP: Post-cardiac arrest hypotension
CCP: All indications
CCP: All indications
DOPamine’s activity is dose-dependent: low doses result in renal, mesenteric, and cerebral vasodilation, improving urine output (and are very unlikely to be used in out-of-hospital care). Medium doses provoke beta stimulation, increasing heart rate and contractility. At high doses, alpha effects dominate, producing systemic vasoconstriction.
Intravenous:
Overdosage of DOPamine is associated with excessively elevated blood pressures. Reduce the rate of administration, or temporarily discontinue infusion until the patient’s condition is stable. DOPamine’s duration of action is relatively short; it is unlikely additional management measures will be required. For protracted overdose situations, consider the use of alpha-adrenergic antagonist agent (phentolamine) for management of hypertension.
Do not administer DOPamine to patients with uncorrected tachydysrhythmias or ventricular fibrillation. DOPamine must not be diluted with alkaline solutions. Use with extreme caution in patients taking monoamine oxidase inhibitor medications; substantially smaller doses will be required to achieve the same clinical effects.
See 'Warnings and Precautions' for details on co-administration with monoamine oxidase inhibitors.